<p>Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - 获取免费报告) 的股价在周一的午盘交易中达到了新的 52 周高点。该公司的股价最高达到 21.49 美元，最后交易价格为 21.4850 美元，成交量为 66811 股。该股票此前收盘价为 21.47 美元。</p>
<h2>分析师评级调整</h2>
<p>多家研究公司对 DAWN 发布了报告。TD Cowen 在 3 月 6 日的报告中将 Day One Biopharmaceuticals 的股票评级从 “买入” 下调至 “持有”。Zacks Research 在 2 月 25 日的报告中将 Day One Biopharmaceuticals 的股票评级从 “强力买入” 下调至 “持有”。Oppenheimer 在 3 月 6 日的报告中重申了对 Day One Biopharmaceuticals 的 “市场表现” 评级。Needham &amp; Company LLC 在 3 月 6 日的报告中将 Day One Biopharmaceuticals 的股票评级从 “买入” 下调至 “持有”。最后，HC Wainwright 在 3 月 10 日的报告中重申了 “中性” 评级，并将 Day One Biopharmaceuticals 的目标价设定为 21.50 美元（下调自 22.00 美元）。一位投资分析师对该股票给予了买入评级，八位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “持有”，共识目标价为 23.29 美元。</p>
<p><strong>查看我们对 DAWN 的最新分析</strong></p>
<h2>Day One Biopharmaceuticals 股票表现</h2>
<p>该股票的 50 日简单移动平均线为 17.61 美元，200 日简单移动平均线为 12.08 美元。该公司的市值为 22.2 亿美元，市盈率为-20.86，贝塔值为-1.74。</p>
<p>Day One Biopharmaceuticals (NASDAQ:DAWN - 获取免费报告) 最近在 2 月 24 日公布了季度财报。该公司报告的每股收益为-0.21 美元，低于分析师一致预期的-0.17 美元，差距为 0.04 美元。该公司在本季度的收入为 5372 万美元，而分析师预期为 4981 万美元。Day One Biopharmaceuticals 的净利润率为-67.85%，股本回报率为-23.43%。分析师预计，Day One Biopharmaceuticals, Inc.在当前年度的每股收益将为-0.72 美元。</p>
<h2>Day One Biopharmaceuticals 的内部交易</h2>
<p>在相关消息中，内部人士 Lauren Merendino 在 2 月 17 日的交易中出售了 5814 股该股票。股票的平均售价为 11.60 美元，总价值为 67442.40 美元。交易后，该内部人士直接持有 60157 股公司股票，价值为 697821.20 美元。这笔交易代表其持股比例减少了 8.81%。该交易已在 SEC 的备案中披露，相关信息可通过 SEC 网站获取。此外，内部人士 Adam Dubow 在 2 月 17 日的交易中出售了 6395 股该股票。股票的平均售价为 11.60 美元，总交易额为 74182.00 美元。交易完成后，该内部人士直接持有 72694 股公司股票，价值为 843250.40 美元。这笔交易代表其持股比例减少了 8.09%。该销售的 SEC 备案提供了更多信息。在过去三个月中，内部人士共出售了 36461 股公司股票，价值为 422948 美元。内部人士持有公司股票的比例为 6.20%。</p>
<h2>Day One Biopharmaceuticals 的机构交易</h2>
<p>大型投资者最近买入和卖出了该公司的股票。Federated Hermes Inc.在第三季度收购了 Day One Biopharmaceuticals 的新股份，价值 39000 美元。Mirae Asset Global Investments Co. Ltd.在第四季度将其在 Day One Biopharmaceuticals 的股份增加了 26.0%。Mirae Asset Global Investments Co. Ltd.现在拥有 4989 股该公司的股票，价值 46000 美元，此前在该期间内又购买了 1029 股。Quarry LP 在第三季度收购了 Day One Biopharmaceuticals 的新股份，价值 49000 美元。Prudential Financial Inc.在第二季度收购了 Day One Biopharmaceuticals 的新股份，价值 69000 美元。最后，CWM LLC 在第四季度将其在 Day One Biopharmaceuticals 的股份增加了 32.4%。CWM LLC 现在拥有 8373 股该公司的股票，价值 78000 美元，此前在该期间内又购买了 2051 股。机构投资者和对冲基金持有该公司 87.95% 的股票。</p>
<h2>关于 Day One Biopharmaceuticals</h2>
<p>(获取免费报告)</p>
<p>Day One Biopharmaceuticals, Inc. NASDAQ: DAWN 是一家临床阶段的生物制药公司，专注于针对肿瘤的靶向治疗的发现和开发。该公司采用精准医疗的方法，利用生物标志物驱动的策略来识别最有可能对其研究化合物产生反应的患者群体。通过集中于经过充分验证的癌症分子驱动因素，Day One 旨在提供具有重要临床益处的首创或最佳治疗。</p>
<p>该公司的产品管线包括多个处于不同开发阶段的小分子候选药物。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Day One Biopharmaceuticals</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Day One Biopharmaceuticals 吗？</h2>
<p>在你考虑投资 Day One Biopharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Day One Biopharmaceuticals 并不在名单上。</p>
<p>虽然 Day One Biopharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

DAWN

<p>Day One Biopharmaceuticals（纳斯达克代码：DAWN）在交易中达到了新的 52 周高点 21.49 美元。该股票收盘价为 21.4850 美元，成交量为 66,811 股。分析师已将该股票评级从 “买入” 下调至 “持有”，共识目标价为 23.29 美元。公司报告的季度每股收益为（0.21 美元），未达到预期，但收入为 5372 万美元，超出预期。内部人士最近出售了股票，机构投资者持有该股票的 87.95%。Day One 专注于靶向肿瘤治疗，并有多个候选药物在开发中</p>

<p>Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report)'s share price reached a new 52-week high during mid-day trading on Monday . The company traded as high as $21.49 and last traded at $21.4850, with a volume of 66811 shares. The stock had previously closed at $21.47.</p>
<div class="lb-trans"><p>Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - 获取免费报告) 的股价在周一的午盘交易中达到了新的 52 周高点。该公司的股价最高达到 21.49 美元，最后交易价格为 21.4850 美元，成交量为 66811 股。该股票此前收盘价为 21.47 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>A number of research firms have issued reports on DAWN. TD Cowen lowered shares of Day One Biopharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Friday, March 6th. Zacks Research lowered shares of Day One Biopharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Wednesday, February 25th. Oppenheimer reiterated a &#34;market perform&#34; rating on shares of Day One Biopharmaceuticals in a report on Friday, March 6th. Needham &amp; Company LLC lowered shares of Day One Biopharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Friday, March 6th. Finally, HC Wainwright reiterated a &#34;neutral&#34; rating and set a $21.50 target price (down from $22.00) on shares of Day One Biopharmaceuticals in a report on Tuesday, March 10th. One investment analyst has rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of &#34;Hold&#34; and a consensus target price of $23.29.</p>
<div class="lb-trans"><p>多家研究公司对 DAWN 发布了报告。TD Cowen 在 3 月 6 日的报告中将 Day One Biopharmaceuticals 的股票评级从 “买入” 下调至 “持有”。Zacks Research 在 2 月 25 日的报告中将 Day One Biopharmaceuticals 的股票评级从 “强力买入” 下调至 “持有”。Oppenheimer 在 3 月 6 日的报告中重申了对 Day One Biopharmaceuticals 的 “市场表现” 评级。Needham &amp; Company LLC 在 3 月 6 日的报告中将 Day One Biopharmaceuticals 的股票评级从 “买入” 下调至 “持有”。最后，HC Wainwright 在 3 月 10 日的报告中重申了 “中性” 评级，并将 Day One Biopharmaceuticals 的目标价设定为 21.50 美元（下调自 22.00 美元）。一位投资分析师对该股票给予了买入评级，八位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “持有”，共识目标价为 23.29 美元。</p>
</div><p><strong>View Our Latest Analysis on DAWN</strong></p>
<div class="lb-trans"><p><strong>查看我们对 DAWN 的最新分析</strong></p>
</div><h2>Day One Biopharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Day One Biopharmaceuticals 股票表现</h2>
</div><p>The stock's 50-day simple moving average is $17.61 and its 200 day simple moving average is $12.08. The company has a market capitalization of $2.22 billion, a PE ratio of -20.86 and a beta of -1.74.</p>
<div class="lb-trans"><p>该股票的 50 日简单移动平均线为 17.61 美元，200 日简单移动平均线为 12.08 美元。该公司的市值为 22.2 亿美元，市盈率为-20.86，贝塔值为-1.74。</p>
</div><p>Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 24th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.04). The firm had revenue of $53.72 million during the quarter, compared to analysts' expectations of $49.81 million. Day One Biopharmaceuticals had a negative net margin of 67.85% and a negative return on equity of 23.43%. On average, analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current year.</p>
<div class="lb-trans"><p>Day One Biopharmaceuticals (NASDAQ:DAWN - 获取免费报告) 最近在 2 月 24 日公布了季度财报。该公司报告的每股收益为-0.21 美元，低于分析师一致预期的-0.17 美元，差距为 0.04 美元。该公司在本季度的收入为 5372 万美元，而分析师预期为 4981 万美元。Day One Biopharmaceuticals 的净利润率为-67.85%，股本回报率为-23.43%。分析师预计，Day One Biopharmaceuticals, Inc.在当前年度的每股收益将为-0.72 美元。</p>
</div><h2>Insider Transactions at Day One Biopharmaceuticals</h2>
<div class="lb-trans"><h2>Day One Biopharmaceuticals 的内部交易</h2>
</div><p>In related news, insider Lauren Merendino sold 5,814 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total value of $67,442.40. Following the transaction, the insider directly owned 60,157 shares of the company's stock, valued at $697,821.20. This trade represents a 8.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Adam Dubow sold 6,395 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $74,182.00. Following the completion of the transaction, the insider directly owned 72,694 shares in the company, valued at $843,250.40. This trade represents a 8.09% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 36,461 shares of company stock worth $422,948. Insiders own 6.20% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Lauren Merendino 在 2 月 17 日的交易中出售了 5814 股该股票。股票的平均售价为 11.60 美元，总价值为 67442.40 美元。交易后，该内部人士直接持有 60157 股公司股票，价值为 697821.20 美元。这笔交易代表其持股比例减少了 8.81%。该交易已在 SEC 的备案中披露，相关信息可通过 SEC 网站获取。此外，内部人士 Adam Dubow 在 2 月 17 日的交易中出售了 6395 股该股票。股票的平均售价为 11.60 美元，总交易额为 74182.00 美元。交易完成后，该内部人士直接持有 72694 股公司股票，价值为 843250.40 美元。这笔交易代表其持股比例减少了 8.09%。该销售的 SEC 备案提供了更多信息。在过去三个月中，内部人士共出售了 36461 股公司股票，价值为 422948 美元。内部人士持有公司股票的比例为 6.20%。</p>
</div><h2>Institutional Trading of Day One Biopharmaceuticals</h2>
<div class="lb-trans"><h2>Day One Biopharmaceuticals 的机构交易</h2>
</div><p>Large investors have recently bought and sold shares of the business. Federated Hermes Inc. acquired a new stake in Day One Biopharmaceuticals during the 3rd quarter worth $39,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Day One Biopharmaceuticals by 26.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,989 shares of the company's stock worth $46,000 after purchasing an additional 1,029 shares during the period. Quarry LP acquired a new stake in Day One Biopharmaceuticals during the 3rd quarter worth $49,000. Prudential Financial Inc. acquired a new stake in Day One Biopharmaceuticals during the 2nd quarter worth $69,000. Finally, CWM LLC boosted its stake in Day One Biopharmaceuticals by 32.4% during the 4th quarter. CWM LLC now owns 8,373 shares of the company's stock worth $78,000 after purchasing an additional 2,051 shares during the period. Institutional investors and hedge funds own 87.95% of the company's stock.</p>
<div class="lb-trans"><p>大型投资者最近买入和卖出了该公司的股票。Federated Hermes Inc.在第三季度收购了 Day One Biopharmaceuticals 的新股份，价值 39000 美元。Mirae Asset Global Investments Co. Ltd.在第四季度将其在 Day One Biopharmaceuticals 的股份增加了 26.0%。Mirae Asset Global Investments Co. Ltd.现在拥有 4989 股该公司的股票，价值 46000 美元，此前在该期间内又购买了 1029 股。Quarry LP 在第三季度收购了 Day One Biopharmaceuticals 的新股份，价值 49000 美元。Prudential Financial Inc.在第二季度收购了 Day One Biopharmaceuticals 的新股份，价值 69000 美元。最后，CWM LLC 在第四季度将其在 Day One Biopharmaceuticals 的股份增加了 32.4%。CWM LLC 现在拥有 8373 股该公司的股票，价值 78000 美元，此前在该期间内又购买了 2051 股。机构投资者和对冲基金持有该公司 87.95% 的股票。</p>
</div><h2>About Day One Biopharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Day One Biopharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Day One Biopharmaceuticals, Inc NASDAQ: DAWN is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.</p>
<div class="lb-trans"><p>Day One Biopharmaceuticals, Inc. NASDAQ: DAWN 是一家临床阶段的生物制药公司，专注于针对肿瘤的靶向治疗的发现和开发。该公司采用精准医疗的方法，利用生物标志物驱动的策略来识别最有可能对其研究化合物产生反应的患者群体。通过集中于经过充分验证的癌症分子驱动因素，Day One 旨在提供具有重要临床益处的首创或最佳治疗。</p>
</div><p>The company's pipeline includes several small-molecule candidates in various stages of development.</p>
<div class="lb-trans"><p>该公司的产品管线包括多个处于不同开发阶段的小分子候选药物。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Day One Biopharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Day One Biopharmaceuticals</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Day One Biopharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Day One Biopharmaceuticals 吗？</h2>
</div><p>Before you consider Day One Biopharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Day One Biopharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Day One Biopharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Day One Biopharmaceuticals 并不在名单上。</p>
</div><p>While Day One Biopharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Day One Biopharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Day One Biopharmaceuticals (NASDAQ:DAWN) Hits New 1-Year High  - What's Next?

Market Beat

Day One Biopharmaceuticals

Day One Biopharmaceuticals（NASDAQ:DAWN）创下 1 年新高 - 接下来会如何发展？